A carregar...
Focus on Nivolumab in NSCLC
Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issue...
Na minha lista:
| Publicado no: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5153403/ https://ncbi.nlm.nih.gov/pubmed/28018902 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2016.00067 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|